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CONCLUSIONS: Given that ChHD affects almost one in ﬁve
MCO members, its negative impact on members’ QoL, work and
activity impairment measures is signiﬁcant and should be con-
sidered by MCOs and employers.
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OBJECTIVE: Psoriasis is a common disease with profound
impact on many facets of life; there is physical impairment as
well as reductions in quality of life deﬁned by psychological,
social, sexual and ﬁnancial parameters. Work productivity,
another important component of patients’ overall well-being, has
also been reported to be impacted by psoriasis. The objective of
this study was to determine whether there exists a relationship
between clinical severity of psoriasis and work productivity.
METHODS: To quantify the impact of psoriasis on work pro-
ductivity, 90 patients were surveyed in a clinic setting. Three
severity groups were created based on Psoriasis Area and Sever-
ity Index (PASI) scores: mild <10, moderate = 10–20, and severe
>20. Work impairment was measured using the Work Produc-
tivity Assessment Index (WPAI); physical and mental health 
statuses were assessed using the SF-8; Anxiety/Depression was
assessed using the HADS; other health and employment infor-
mation were also collected. RESULTS: One-third of all subjects
were unemployed at the time of the study with 16.7% of these
subjects (5.5% of all 90 subjects) reporting that they were unem-
ployed because of their psoriasis. A greater percentage of patients
in the moderate and severe groups attributed their unemploy-
ment to psoriasis (33% for each), compared with the mild group
(9.5%). There was a trend toward increasing impairment while
at work with increasing psoriasis severity (severe 24.4%, mod-
erate 17.7% and mild 13.5%). With respect to the percent with
activity impairment, there was a statistically signiﬁcant differ-
ence between the severe group (42%) and the mild group
(20.2%)[all p < 0.05]. CONCLUSIONS: Psoriasis is associated
with work productivity impairment, and the degree of work
impact, missed work, physical and mental health condition and
anxiety/depression status tends to be greater in patients with
more severe skin involvement. These ﬁndings support the need
for aggressive but appropriate treatment of moderate-to-severe
psoriasis.
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Up to now, there are few economic analyses which construct
models taking account of tobacco-associated diseases in Japan.
OBJECTIVES: To develop Markov-model, including various
tobacco-associated diseases to evaluate effects of nicotine-
replacement therapy (NRT) and smoking cessation guidance
therapy. METHODS: To identify various tobacco-associated 
diseases and markov transition probabilities, we organized a
committee including expert physicians. With expert interview,
we developed a Markov-model. RESULTS: We identiﬁed 19
tobacco-associated diseases as major results of smoking, accord-
ing to “Health Risk Appraisal”. The 19 diseases are as follows;
10 cancers—oropharyngeal cancer, esophageal cancer, gastric
cancer, hepatic cancer, rectal cancer, pancreatic cancer, lung
cancer, cervical cancer, renal cancer and bladder cancer; 
4 cardiovascular diseases—hypertensive heart disease, ischemic
heart disease, aneurysm and apoplexy; and 5 other diseases—
pneumonia, chronic bronchitis, asthma, gastric ulcer and cir-
rhosis. Tobacco is thought to increase incidence rate of those 19
diseases. We constructed four node Markov model, “Success (of
smoking cessation)” “Failure” “Death” and “Sick”. “Sick” node
consists of 19 diseases. We also considered a combination of
major diseases. In order to avoid many branches, we settled the
transition probabilities of diseases as a cumulative function of
incidence of each disease. The main assumptions are as follows;
1) Only one disease occurs during each cycle; 2) The risk of each
disease increases as cumulative tobacco consumption increases;
and 3) Smoking affects the incidence rate of the 19 diseases but
does not affect mortality rate from those diseases. One cycle 
in Markov chain is set to 5 year. For future cost-effectiveness
analysis of smoking cessation therapy, we set cost as well as 
transition probability on each branch. CONCLUSIONS: We
developed Markov-model, including various tobacco-associated
disease. In the future, we will take cost-effectiveness analysis to
evaluate smoking cessation therapy using this model.
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OBJECTIVES: The “Smoking Effects Inventory” (SEI) assesses
the degree to which subjects experience both desirable and aver-
sive effects from smoking. To date, no formal psychometric
analyses of the SEI have been published. We therefore tested the
validity and reliability of the pre-speciﬁed grouping of items on
the SEI. METHODS: Data came from three Phase II clinical
trials (n = 626, n = 627, n = 312) of varenicline, developed for
smoking cessation, using an adapted version of the SEI with 12
items (one item on enjoying smoking was added). Each item was
scored on a seven-point scale (one = “Not at all” to seven =
“Extremely”) in response to the experience of the reinforcing
effects of smoking. The pre-speciﬁed domains and single-item
scales were Satisfaction (satisfaction, good taste, enjoying
smoking); Psychological Reward (calming, feeling awake, reduc-
ing irritability, helping concentration, reducing hunger); Aversion
(dizziness, nausea); Enjoyment of Respiratory Tract Sensations;
and Craving Reduction. Conﬁrmatory factor analyses and inter-
nal consistency reliability analyses (Cronbach’s alpha) on multi-
item domains were performed at baseline in each of the three
trials. RESULTS: The postulated multidimensional framework of
the SEI was supported by conﬁrmatory factor analysis in each of
the three studies. Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) in the three trials exceeded 0.90 (CF = 0.94,
0.95, 0.94; NNFI = 0.92, 0.93, 0.92). Cronbach’s alpha exceeded
0.80 in the three studies for the Satisfaction domain (Cronbach’s
alpha: 0.82, 0.85, 0.84) and the Psychological Reward domain
(0.84, 0.82, 0.83) but was less than 0.60 for the Aversion domain
(0.50, 0.55, and 0.56). CONCLUSION: The validity of the pos-
tulated multidimensional framework of the SEI is conﬁrmed and
supported by the data. Although reliability (internal consistency)
of the Aversion domain was not high, excellent reliability was
